Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06764875
Title	A Phase III Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Recruitment	Not yet recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	AstraZeneca
Indications	stomach cancer gastroesophageal junction adenocarcinoma
Therapies	Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab Cisplatin + Fluorouracil + Pembrolizumab + Trastuzumab AZD2936 + Capecitabine + Oxaliplatin + Trastuzumab AZD2936 + Cisplatin + Fluorouracil + Trastuzumab AZD2936 + Fluorouracil + Trastuzumab deruxtecan AZD2936 + Capecitabine + Trastuzumab deruxtecan
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| NLD \| ITA \| HUN \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUT \| AUS